ORYZF News and Press, Oryzon Genomics S.A. From 06/17/25

Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 27 70-90% of PMS patients show autistic related features, including aggression Agitation/Aggression in PMS and other ASD-related patient subpopula...

Foro MedCap 2025 BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in ...

2025-05-12 09:45:41 ET More on Oryzon Genomics S.A. Historical earnings data for Oryzon Genomics S.A. Financial information for Oryzon Genomics S.A. Read the full article on Seeking Alpha For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.03

Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project) ...

Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafid...

Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US institutional investor Proceeds to fun...

In combination with atezolizumab or durvalumab Study conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveragi...

BIO-Europe Spring 2025 Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapi...

A non-interventional study published in Frontiers in Psychiatry Psychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsets Study provides clinical scales and thresholds for patient selection in future clinical ...

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standards O...